You are here : Home > News Archive > CARBOGEN AMCIS AG Appoints Johns...
CARBOGEN AMCIS AG Appoints Johnson as HiPo Business Manager

Industry leader Charlie Johnson to lead high potency business

26 January 2009

BUBENDORF, Switzerland (Jan. 23, 2009) — Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and active pharmaceutical ingredient (API) manufacturing company, recently announced the addition of its new High Potency Business Manager, Charlie Johnson.

“This key new appointment demonstrates CARBOGEN AMCIS’ commitment to maintain its position as a leading provider of high potency services to the pharma and biotech sectors.  Charlie Johnson will continue the momentum CARBOGEN AMCIS has gained in the provision of HiPo services.  He will also be a valuable addition to the internal project team, helping to shape customer strategy in the highly potent area,” said Rhona McIntyre, commercial director for CARBOGEN AMCIS AG. 

Johnson’s expertise is built on more than 16 years working within the pharmaceutical industry. During this time, he has been based in Italy and England, while holding positions with UQUIFA and Avecia Pharmaceuticals (now Piramal Healthcare), and Zeneca (now AstraZeneca).

Johnson will lead the commercial roll-out of the new 4,300m2 large scale high potency facility in Bavla, India which is due for completion mid-2009.  He will also play a pivotal role in expanding the company’s high potency offer through exploring new technology platforms and other business opportunities. Johnson’s experience combines both commercial and operational roles in the high potency and contract manufacturing arenas. This extends to both conventional highly potent chemistry and antibody drug conjugation offerings.

“I was attracted to CARBOGEN AMCIS because of its ability to provide the full continuum of HiPo services, from bench to large-scale manufacturing,” said Johnson. “Once the Bavla facility is completed, CARBOGEN AMCIS’ unmatched production capabilities and end-to-end API operations will present significant advantages for customers.”

###

CARBOGEN AMCIS AG is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.

Source: CARBOGEN AMCIS AG, Bubendorf, Switzerland

News
11 August 2016
Dishman Celebrates a Decade of Success Since Acquisition of CARBOGEN AMCIS

14 July 2016
CARBOGEN AMCIS Sites at Aarau and Neuland in Switzerland Successfully Pass FDA Inspection

31 May 2016
CARBOGEN AMCIS Expands Operations in Bubendorf


Events
World ADC Berlin

DCAT week - New York City